1472 related articles for article (PubMed ID: 21068524)
1. Emerging oral antiplatelet therapies for acute coronary syndromes.
Pollack CV
Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
[TBL] [Abstract][Full Text] [Related]
2. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
White HD
Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598
[TBL] [Abstract][Full Text] [Related]
3. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
Packard KA; Campbell JA; Knezevich JT; Davis EM
Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
[TBL] [Abstract][Full Text] [Related]
4. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
[TBL] [Abstract][Full Text] [Related]
5. New antiplatelet agents in the treatment of acute coronary syndromes.
Sabouret P; Taiel-Sartral M
Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
[TBL] [Abstract][Full Text] [Related]
7. Ticagrelor: a novel reversible oral antiplatelet agent.
Nawarskas JJ; Clark SM
Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.
Golino P
J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
10. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes.
Cheng JW
Clin Ther; 2012 Jun; 34(6):1209-20. PubMed ID: 22521881
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
Husted S
Postgrad Med; 2011 Nov; 123(6):79-90. PubMed ID: 22104457
[TBL] [Abstract][Full Text] [Related]
13. Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.
Serebruany VL; DiNicolantonio JJ
Thromb Haemost; 2013 Jul; 110(1):5-10. PubMed ID: 23743577
[TBL] [Abstract][Full Text] [Related]
14. Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes.
Berger JS
Am J Cardiol; 2013 Sep; 112(5):737-45. PubMed ID: 23751937
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet therapy in acute coronary syndromes.
Grove EL; Würtz M; Thomas MR; Kristensen SD
Expert Opin Pharmacother; 2015; 16(14):2133-47. PubMed ID: 26293612
[TBL] [Abstract][Full Text] [Related]
16. Platelet protease-activated receptor antagonism in cardiovascular medicine.
Wiisanen ME; Moliterno DJ
Coron Artery Dis; 2012 Sep; 23(6):375-9. PubMed ID: 22781741
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet options for secondary prevention in acute coronary syndromes.
Silvain J; Cayla G; O'Connor SA; Collet JP; Montalescot G
Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1403-15. PubMed ID: 22059790
[TBL] [Abstract][Full Text] [Related]
18. Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome.
Ramaraj R; Movahed MR; Hashemzadeh M
J Interv Cardiol; 2011 Jun; 24(3):199-207. PubMed ID: 21198849
[TBL] [Abstract][Full Text] [Related]
19. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
20. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Steg PG; James S; Harrington RA; Ardissino D; Becker RC; Cannon CP; Emanuelsson H; Finkelstein A; Husted S; Katus H; Kilhamn J; Olofsson S; Storey RF; Weaver WD; Wallentin L;
Circulation; 2010 Nov; 122(21):2131-41. PubMed ID: 21060072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]